PATENT CLAIM ANALYSIS

Application Number: 15744207
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (notably neuropathic pain, neurodegenerative disorders, ischemic brain injury and inflammatory intestinal conditions). Additionally, the invention provides a method to enhance the therapeutic effect of amitriptyline for its common indications. The method of the invention involves combining amitriptyline with another HC-blocking agent, mefloquine.

Claim (Index 5):
The therapeutic composition according to  claim 1  for use according to any one of  claims 2  to  4 , wherein mefloquine dose regimen is within the range of about 10 \u03bcg to 50 mg per day, preferably between 100 \u03bcg and 25 mg per day, more preferably between 1 mg and 25 mg per day.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 86.0
- Lexical Diversity: 1.47541
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14907221', '11295730', '13420111', '15834428', '14833041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7036731586176733
- 35 USC 102 Novelty (BERT): 0.5416566959900392
- Combined Prediction Score: 0.6874715123549099
- Mean Citation Score: 288.85656
- Max Citation Score: 393.6475
- Similarity Product: 215.4911108212173

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test